v3.26.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Financial Performance

Summary segment financial performance measures evaluated by the CODM as of December 31, 2025 and 2024 and for the years then ended is as follows:

 

       
   Segment Assets at December 31, 
   2025   2024 
Digital asset treasury segment  $513,964,900   $- 
Clinical stage bio-technology segment   5,181,535    3,721,624 
Total assets  $519,146,435   $3,721,624 

 

Digital asset treasury segment

 

       
   For the years ended December 31, 
   2025   2024 
Loss from operations  $(2,765,292)  $- 
Other income (expense) (a)   24,117    - 
Unrealized loss on digital assets holdings   (22,010,362)   - 
Total loss before income taxes  $(24,751,537)  $- 

 

Clinical stage bio-technology segment

 

       
   For the years ended December 31, 
   2025   2024 
Loss from operations  $(17,340,774)  $(12,433,792)
Other income (expense) (a)   (11,052)   236,224 
Total loss before income taxes  $(17,351,826)  $(12,197,568)

 

(a)Other income (expense) consists of interest income and interest expense.

 

The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.

 

         
   For the years ended December 31, 
   2025   2024 
Digital asset treasury segment total loss before income taxes  $(24,751,537)  $- 
Clinical stage bio-technology segment total loss before income taxes   (17,351,826)   (12,197,568)
Consolidated total loss before income taxes  $(42,103,363)  $(12,197,568)